Redx Pharma's proprietary Redox Switch approach has allowed the company to secure a broad portfolio of intellectual property covering around 200 families of compounds — each based upon an existing commercial or late clinical-stage drug. This novel medicinal chemistry approach has provided us with fast and efficient access to an extensive pipeline of new drug candidates across multiple high value therapeutic applications. The structural similarity of these compounds to parent drugs that are well-characterised and understood reduces the overall risk profile for Redx Pharma's programs and cuts development times.
To date, the Redox Switch approach has been validated across more than 30 different chemical classes and 11 different therapeutic areas.
Redx Pharma is currently progressing programs through development in the following therapeutic areas:
In each case, Redx Pharma has secured novel IP around new compounds which have the potential to produce significant improvements in efficacy, safety and usability resulting in better treatments for patients.